Gonapeptyl 3.75mg. 104mg / ml Injection
PDF Leaflet Revision Date: 28 November 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of advanced prostate carcinoma, symptomatic uterine myomas, endometriosis, and central precocious puberty.
Dosage (summary)
3.75 mg every 4 weeks for adults; children based on weight.
Special Populations
- Children under 8 years
- Patients with spinal cord compression
Pregnancy & Breastfeeding
Contraindicated in pregnancy and lactation.
Key Drug Interactions
- Oestrogen-containing products
Contraindications
- Hypersensitivity
- Spinal cord compression
- Hormone independent prostate carcinoma
- Pregnancy
- Lactation
Common side effects
- Injection site pain
- Depressive mood
- Fatigue
- Nausea
- Gynecomastia
Counselling Points
- Report any unusual bleeding
- Use non-hormonal contraception
- Monitor for bone density loss
Serious warnings
- Transient increase in testosterone may worsen symptoms
- Monitor PSA and testosterone levels
Important Disclaimer
The Gonapeptyl 3.75mg. 104mg / ml Injection professional information leaflet below is the property of Ferring and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
